Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 300 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Los Angeles, CaliforniaAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06568562RecruitingPhase 2
XL092 for advanced prostate cancer after PSMA therapy
This trial tests a new oral drug, XL092, for men with metastatic castration-resistant prostate cancer that has progressed after PSMA-targeted radiation therapy (Lu-177 PSMA-617). It aims to see if the drug can slow down the cancer.
Salt Lake City, UtahAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Phoenix, ArizonaAges 18 years+ - NCT03237702Recruiting
Study uses urine tests to understand prostate cancer
This study collects a small urine sample around the time of a prostate biopsy to look for chemical “signals” that may explain dangerous prostate cancer behavior. Your results are not shared with you, but the information may help researchers improve understanding and future care.
TaipeiAges 30–100 - NCT06343077RecruitingPhase 2
Hiltonol injection for prostate cancer on active surveillance
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT06926283RecruitingPhase 1
Study of DXC008 for advanced prostate and other solid tumors
This trial tests a new drug called DXC008 for people with advanced solid tumors, including prostate cancer, that have not responded to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Changsha, HunanAges 18–75 - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
San Francisco, CaliforniaAges 18 years+ - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06865547Enrolling by invitation
Managing metastatic hormone-sensitive prostate cancer with apalutamide
This trial tests a proactive management approach for men with metastatic hormone-sensitive prostate cancer who are starting apalutamide. It aims to see if this model helps improve how well the treatment works and how patients feel.
Guangzhou, GuangdongAges 18 years+ - NCT05560659RecruitingPhase 2
SABR plus Lu-PSMA for limited prostate cancer spread
This trial studies whether adding Lu-PSMA therapy to targeted, high-precision radiation (SABR) can better control prostate cancer that has spread to a small number of lymph nodes or bones. It may help by treating both visible spots with the most accurate radiation and PSMA-targeted drug therapy.
St Leonards, New South WalesAges 18 years+ - NCT06399757RecruitingPhase 1/Phase 2
A study of APL-5125 for advanced solid tumors
This trial tests a new drug called APL-5125 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. If you have certain types of advanced cancer, this study may offer a new option.
Duarte, CaliforniaAges 18 years+ - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05885009Recruiting
Liquid biopsy test to guide treatment in metastatic prostate cancer
This study looks at using a simple blood test (liquid biopsy) to read tumor DNA and understand how it could affect treatment decisions. It is for adults with metastatic prostate cancer who are about to start, are receiving, or recently finished treatment.
BarcelonaAges 18 years+ - NCT07001241RecruitingPhase 2
Telehealth exercise for fatigue in rural cancer survivors
This study tests a 12-week home exercise program delivered via video calls, designed to help reduce fatigue and improve physical function in people who have finished treatment for breast or prostate cancer and live in rural areas.
Aurora, ColoradoAges 18–89 - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06138067Recruiting
Navigator program to help cancer patients join clinical trials
This study tests if a patient navigator can help more people with prostate or kidney cancer enroll in clinical trials. You may be assigned to work with a navigator who helps find a trial that fits your needs.
Baltimore, MarylandAges 18 years+ - NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT07181473RecruitingPhase 1
Safety of TJ101 for advanced solid tumors
This trial tests a new drug called TJ101 for people with advanced solid tumors who have tried standard treatments or have no standard options. It aims to see if the drug is safe and how well it works.
Orlando, FloridaAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT06990880RecruitingPhase 1/Phase 2
Study of GSK5458514 alone or with other drugs for prostate cancer
This trial tests a new drug, GSK5458514, either alone or with other cancer treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if the drug can slow down the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 300 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.